Researchers at the University of Helsinki have identified CDNF as a potential breakthrough treatment for ALS, showing its efficacy in improving motor behavior and reducing paralysis symptoms in animal models, thereby offering hope for more effective ALS therapies.
A team of researchers at the University of Helsinki, along with their collaborators, have discovered a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). The drug, cerebral dopamine neurotrophic factor CDNF has shown positive results in prolonging lifespan and alleviating disease symptoms in animal studies involving rats and mice.
Understanding ALS
Amyotrophic lateral sclerosis (ALS) is a rapidly progressing fatal neurodegenerative disease that affects the nerve cells in the brain and spinal cord. Specifically, a selective degeneration of motoneurons occurs in the spinal cord, leading to muscle atrophy and paralysis.
Most patients with ALS die from respiratory failure, usually within 1 to 3 years from symptom onset. There is no cure for ALS, and the only drug available in Europe, riluzole, only prolongs ALS patient survival by a couple of months.
Assistant professor Merja Voutilainen and researchers from the Regenerative Neuroscience Group, Faculty of Pharmacy and Institute of Biotechnology, University of Helsinki, together with their national and international collaborators, investigated the therapeutic effect of a protein called cerebral dopamine neurotrophic factor (CDNF) in several cellular and animal models of ALS.
Research on CDNF
The CDNF protein, discovered by Professor Mart Saarma laboratory in 2007, is mostly found in the endoplasmic reticulum (ER) within cells. ER is an important cell organelle mainly involved in the synthesis and maturation of circa one-third of all proteins in the cell. CDNF has previously shown therapeutic potential in Parkinson’s disease.
In this study, the Regenerative Neuroscience Group used three animal models that were genetically modified to express human mutations (TDP43-M337V and SOD1-G93A) affecting ALS patients.
Their goal was to investigate whether CDNF can affect disease development in the rodent models of ALS and elucidate its mechanism of action. They were particularly interested in studying ER stress, which is a cellular response to protecting cells and its proteins. If ER stress becomes chronic, as is the case in many neurological diseases, it can cause cell death.
Study Findings
“We found that administration of CDNF to ALS mice and rats significantly improves their motor behavior and halts the progression of paralysis symptoms. Symptom amelioration is reflected in an increased number of surviving motoneurons in the spinal cord of the animals compared to rodents that did not receive CDNF. Our experiments suggest that CDNF may rescue motoneurons by reducing the ER stress response and, therefore, cell death. Importantly, ER stress was present in all our animal models, independently of the specific genetic mutations,” says Dr. Francesca De Lorenzo, lead author of the study, from the University of Helsinki.
Professor Michael Sendtner from the University of Würzburg, Germany, one of the world’s leading researchers in the field of ALS research and co-author of the study, comments: “This study opens the way to a rational therapy to counteract one of the most severe cellular pathologies in ALS: ER stress.”
“CDNF holds great promise for the design of new rational treatments for ALS”, says Dr. Merja Voutilainen, Assistant professor at the University of Helsinki and the director and senior author of the study.
Reference: “CDNF rescues motor neurons in models of amyotrophic lateral sclerosis by targeting endoplasmic reticulum stress” by Francesca De Lorenzo, Patrick Lüningschrör, Jinhan Nam, Liam Beckett, Federica Pilotto, Emilia Galli, Päivi Lindholm, Cora Rüdt von Collenberg, Simon Tii Mungwa, Sibylle Jablonka, Julia Kauder, Nadine Thau-Habermann, Susanne Petri, Dan Lindholm, Smita Saxena, Michael Sendtner, Mart Saarma and Merja H Voutilainen, 16 March 2023, Brain.
DOI: 10.1093/brain/awad087
